US3908003A - Enrobed solid hydrophobic tableting lubricants and compositions - Google Patents
Enrobed solid hydrophobic tableting lubricants and compositions Download PDFInfo
- Publication number
- US3908003A US3908003A US449171A US44917174A US3908003A US 3908003 A US3908003 A US 3908003A US 449171 A US449171 A US 449171A US 44917174 A US44917174 A US 44917174A US 3908003 A US3908003 A US 3908003A
- Authority
- US
- United States
- Prior art keywords
- lubricant
- enrobed
- tableting
- hydrophilic
- solid hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000314 lubricant Substances 0.000 title claims abstract description 83
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 35
- 239000007787 solid Substances 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims description 28
- 238000004090 dissolution Methods 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 20
- 108010010803 Gelatin Proteins 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 10
- 235000012222 talc Nutrition 0.000 claims description 10
- 229910052623 talc Inorganic materials 0.000 claims description 10
- 235000013539 calcium stearate Nutrition 0.000 claims description 9
- 239000008116 calcium stearate Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 229920000084 Gum arabic Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 239000000205 acacia gum Substances 0.000 claims description 5
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 claims description 4
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 28
- 238000005461 lubrication Methods 0.000 description 6
- 230000000181 anti-adherent effect Effects 0.000 description 5
- 239000003911 antiadherent Substances 0.000 description 5
- 238000005056 compaction Methods 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- -1 glidants Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Definitions
- the rate of disintegration of the compact should ideally not be impeded by the processing or additives required to convert the active constituents into a convenient, stable and easily ingestible oral dosage form.
- the conventional procedure for making compacts requires the addition of a lubricant to the mixture before compression. Compression is accomplished by subjection of the tablet mix to high pressures by moveable punches operating in a die wherein the tablet mix is confined.
- the lubricant generally fine particles of solid material typified by such hydrophobic, antiadherent materials as metallic stearates, fatty acids, talc and natural and synthetic waxes, is necessary to allow the ready ejection of the formed compact and to prevent the binding of the punches in the die. Lubrication is required only at the tablet-die interface to prevent sticking of the newly formed compact to the die walls.
- existing practical approaches to tablet lubrication require homogeneous distribution of lubricant within the entire tablet granulation (see for example: Remingtons Practice of Pharmacy, 12th edition, 1961, Mack Publishing Co., Page 448).
- US. Pat. No. 3,l58,l l 1 discloses a timed spray to lubricate thepunch and die surfaces, the lubricant being dispersed in and distributed by an aerosol propellant.
- U.S. Pat. No. 3,042,531 teaches a dual cycle compression system in which a tablet containing only lubricant and carrier is first compressed within a die and then ejected leaving a residue of lubricant on the punch and die surfaces providing external lubrication for a second active granulation which is subsequently introduced and compressed.
- the invention sought to be patented in a principal composition aspect resides in the concept of finely divided particles of solid hydrophobic tableting lubricant, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath.
- the tangible embodiments of the principal composition aspect of the invention possess the applied use characteristic of supplying necessary lubrication at points of high shear when present in a tableting formulation subject to compression according to standard methods for compact formation.
- the hydrophilic envelope will selectively rupture at points of high shear such as the compact-die wall interface thus releasing the entrapped lubricant where it is needed.
- the enrobed solid hydrophobic lubricant particles in the interior of the compact as well as on the top and bottom surfaces will remain intact and present none of the antiadherent, hydrophobic characteristic properties of conventional, unprocessed lubricants.
- the invention sought to be patented in a second composition aspect resides in the concept of a solid compact comprising finely divided particles of solid hydrophobic tableting lubricant, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath.
- the tangible embodiments of the second composition aspect of the invention possess the applied use characteristic of being compacts with improved disintegration characteristics capable of formation by standard tableting procedures known in the art.
- the invention sought to be patented in a principal process aspect resides in the concept of a process for the production of a compact which comprises incorporating in a mixture to be compacted finely divided particles of solid hydrophobic tableting lubricant, a substantial proportion of said particles being enrobed in a hydrophilic friable sheath, and applying thereto a sufficient compressive force.
- the conventional tableting excipients such as binders, fillers, glidants, disintegrants, flavors and colorants may be mixed with a specially prepared enrobed solid hydrophobic lubricant before compaction.
- This solid hydrophobic lubricant has previously been treated to enclose it within a non-hydrophobic, friable sheath or envelope.
- This relatively inelastic envelope is designed to selectively rupture only at areas of high shear during compaction, such as the tablet-die wall interface, and remain intact in the interior of the tablet.
- the entrapped solid hydrophobic lubricant released from the ruptured enrobed lubricant particle functions only where actually required.
- the enrobed lubricant particles in the interior of the tablet remain intact and present none of the anti-adherent, hydrophobic properties of conventional, unprocessed lubricants. Thus, dispersal of fluids within the tablet interior is facilitated and the availability of the contained active ingredient is improved.
- the enrobed particles on the top and bottom of the tablet also remain substantially intact, thus providing free entry of the dissolution fluid. These surface particles, while subjected to high compressive forces during compaction are not ruptured, because no true shearing or sliding forces are exerted on these areas. Shear, in this context, is considered as stress resulting from applied forces that cause two contiguous surfaces to slide relatively to each other in a direction parallel to their plane of contact.
- the designed mechanical function of this method may be visually indicated by dye tracers incorporated in the envelope surrounding the lubricant particle.
- the sides or lands of the other wise uncolored compressed tablets show dye streaks parallel to the path of ejection, while examination of bisected tablets show intact unchanged enrobed particles in the tablet interior.
- the enrobed solid hydrophobic lubricants of the present invention can be prepared by a variety of processes, such as:
- micropellets Formation of hydrophilic micropellets from geletin, gum arabic, methyl cellulose, polyvinyl, alcohol, or the like, said micropellets containing solid hydrophobic tableting lubricant particles.
- the technique for preparation of micropellets containing particulate material is described in N. Tanaka, S. Takino, and I. Utsumi, J. Pharm. Sci., 52, 664 (1963).
- any of the various solid hydrophobic tableting lubricants may be used in this invention.
- these are magnesium stearate, calcium stearate, talcum, fatty acids, stearic acid, and powdered vegetable stearine.
- Other suitable tableting lubricants will readily suggest themselves and the utilization in the practice of the invention of any of a vast number of substances suitable as lubricants is well within the skill of the art.
- hydrophilic substances may be utilized as the coating materials in the present invention.
- hydrophilic mate ials contemplated by the present invention are such substances as gelatin, gum arabic, methyl cellulose, carboxymethylcellulose, polyvinyl alcohol, mannitol, polyethylene glycol 4,000, 6,000, and 20,000, and other hydrophilic materials which will be obvious to those skilled in the art.
- hydrophilic mate ials contemplated by the present invention are such substances as gelatin, gum arabic, methyl cellulose, carboxymethylcellulose, polyvinyl alcohol, mannitol, polyethylene glycol 4,000, 6,000, and 20,000, and other hydrophilic materials which will be obvious to those skilled in the art.
- the thickness of the enrobing material which surrounds the lubricant particles is not critical. The shearing forces generated during compaction are extremely large and are more than sufficient to rupture the various sheath thicknesses which may
- the optimal thickness of the friable sheath will vary with the particular substances utilized, or the particular coating procedures used; however, the optimal thickness, or optimal range of thicknesses for a particular combination of lubricant and sheathing material may be readily determined by those skilled in the art.
- the compacts prepared utilizing the present invention may be multilayer compacts and have various different shapes and sizes. Further, that these compacts once formed may be coded and/or coated by a variety of procedures well-known to those skilled in the art. Still further, they may be subjected to a polishing procedure or other routine processes which have been carried out on compacts prior to this invention.
- Additional advantages of this invention include the improvement of physical properties of compressed tablets even where availability of the actives is not a factor. As an example, harder, less friable and more rapidly disintegrating tablets may be obtained with the enrobed solid hydrophobic lubricant particles of the invention than with an equivalent quantity of unprocesses lubricant.
- Polyethylene glycol 4000 g. is heated until molten (6065 C. and dry, finely powdered magnesium stearate U.S.P. (10 g.) is added with mechanical stirring. This stirred dispersion is cooled to room temperature (ca. 25 C.) and chilled further with solid carbon dioxide. The solid is milled through a US. No. 30 screen producing the enrobed tableting lubricant which is suitable for use in conventional tableting procedures.
- EXAMPLE ll 33% Magnesium Stearate Enrobed in Gelatin To a suspension of gelatin (40 g.) in water (200 g.) is added finely powdered magnesium stearate USP. (20 g.) with rapid stirring. This mixture is warmed on a steam bath to form a solution and poured into mineral oil (600 g.) heated to ca. 5560 C. The total mixture is stirred at 1822 r.p.m. for 5 minutes and quickly cooled to ca. 5 C. producing gelatin micropellets containing magnesium stearate. The micropellets are washed with isopropanol and dried. The dried micropellets produced in this manner are suitable for use as a lubricant in conventional tableting procedures.
- EXAMPLE lV Talc Enrobed in Polyethylene Glycol 6000 by Spray Chilling Dry powdered talc (25 g.) is suspended in molten polyethylene glycol 6,000 (250 g.) and stirred until homogeneous. This suspension is sprayed into a chilled chamber with cold air causing the polyethylene glycol 6,000 to solidify about the tale particles. In this manner talc particles coated with polyethylene glycol 6,000 may be obtained which are suitable for use as a tableting lubricant in a conventional tableting procedure.
- Tablet disintegration time was reduced from 23' minutes for a control tablet containing a conventional lubricant to 17 minutes for a tablet containing an equivalent amount of the enrobed lubricant.
- T and T is time in minutes necessary for dissolution of 50% and 80%
- said sheathing material being selected from the group consisting of mannitol, polyethylene glycol 4,000, 6,000, and 20,000, gelatin, methyl cellulose, carboxymethylcellulose, gum arabic, and polyvinyl alcohol; said enrobed tableting lubricant imparting a reduction in dissolution time to a compacted pharmaceutical dosage form when incorporated in said compacted pharmaceutical dosage form, as compared to said lubricant when not enrobed.
- composition of claim 1 wherein the solid hydrophobic tableting lubricant is magnesium stearate and the hydrophilic friable sheathing material is poly ethylene glycol 4000.
- composition of claim 1 wherein the solid hydrophobic tableting lubricant is magnesium stearate and the hydrophilic friable sheathing material is gelatin.
- composition of claim 1 wherein the solid hydrophobic tableting lubricant is calcium stearate and the hydrophilic friable sheathing material is gelatin.
- a compressed pharmaceutical medicament tablet containing as tableting lubricant a tableting lubricant composition consisting essentially of micropellets of finely divided particles of solid hydrophobic tableting lubricant selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, talcum, and powdered vegetable stearine, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath, said sheathing material being selected from the group consisting of mannitol, polyethylene glycol 4,000, 6,000, and 20,000, gelatin, methyl cellulose, carboxymethylcellulose, gum arabic, and polyvinyl alcohol; said tablet having imparted, by said enrobed lubricant, reduced disintegration time compared to said lubricant if not enrobed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Conventional solid hydrophobic tableting lubricants enrobed in a hydrophilic friable sheath are disclosed. The utilization of these enrobed lubricants with conventional tableting equipment makes possible the preparation of compacted tablets with improved dissolution times.
Description
United States Patent 1191 1111 3,908,003
Hersh Sept. 23, 1975 [54] ENROBED SOLID HYDROPHOBIC 3,382,150 5/1968 Grass et al.... 424/32 TABLETING LUBRICANTS AND 3,518,343 6/1970 Wolsh et al... 424/44 3,518,344 6/1970 Wolsh et a1... 424/44 COMPOSITIONS 3,518,345 6/1970 Dinos et al.... 424/44 [75] Inventor: Marvin Hersh, Strafford, Pa, 3,619,462 11/1971 Dinos et al 264/300 [73] Assignee: American Home Products OTHER PUBLICATIONS Corporation, New York, N.Y. Little et al., Tablet Making, 2nd Ed. (1963), pp. 22 F1 d. M 7, 1974 1 l 8 M 64-65 Northern Pub. Co. Liverpool, England. [21] Appl, No.: 449,171
Related Application Data Primary Examirier- Shep K. Rose [63] Continuation-impart of Ser. No. 159,569, July 2, Attorney, Agent, or FirmRobert Wiser 1971, abandoned.
[52] U.S. Cl. 424/32; 252/10; 264/300; [57] S R C 424/357; 424/365 Conventional solid hydrophobic tableting lubricants [51] Int. Cl. A61K 27/00 enrobed in a hydrophilic friable sheath are disclosed. [58] Field of Search 424/32-38, The utilization of these enrobed lubricants with con- 424/357, 365; 264/300; 252/10 ventional tableting equipment makes possible the preparation of compacted tablets with improved disso- [56] References Cited lution times.
UNITED STATES PATENTS 6 Cl N D 3,210,208 10/1965 Grass et al. 106/148 o rawmgs ENROBED SOLID HYDROPI-IOBIC TABLETING LUBRICANTS AND COMPOSITIONS CROSS-REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of US. Patent application Ser. No. 159,569, filed July 2, l97l, now abandoned.
BACKGROUND OF THE INVENTION em. The rate of disintegration of the compact should ideally not be impeded by the processing or additives required to convert the active constituents into a convenient, stable and easily ingestible oral dosage form. However, in practice, it is usually necessary to include in the tableting composition agents which impart physical characteristics essential for manufacture with existing compaction equipment, but having adverse effects on tablet disintegration and thus on the availability of the active components.
The conventional procedure for making compacts requires the addition of a lubricant to the mixture before compression. Compression is accomplished by subjection of the tablet mix to high pressures by moveable punches operating in a die wherein the tablet mix is confined. The lubricant, generally fine particles of solid material typified by such hydrophobic, antiadherent materials as metallic stearates, fatty acids, talc and natural and synthetic waxes, is necessary to allow the ready ejection of the formed compact and to prevent the binding of the punches in the die. Lubrication is required only at the tablet-die interface to prevent sticking of the newly formed compact to the die walls. However, existing practical approaches to tablet lubrication require homogeneous distribution of lubricant within the entire tablet granulation (see for example: Remingtons Practice of Pharmacy, 12th edition, 1961, Mack Publishing Co., Page 448).
The inclusion of an anti-adherent lubricant between granules intended for compression and cohesion in a compact is a paradoxical reality of tableting. Cohesion of adjacent granules is desired to form a structurally adequate compact; however, wh en anti-adherent lubricant particles are interspersed between these granules, cohesion is reduced and a weak compact results. Similarly, the presence of hydrophobic lubricant particles in a compressed matrix surrounding active material which is intended for rapid dissolution and absorption is a negative design. The movement of fluid through intergranular passages is desired in order to initiate the disintegration of the compressed tablet thus allowing the active components to be absorbed by the host. The presence throughout the tablet of hydrophobic lubricant particles, however, impedes this distribution of solvent into the tablet interior, thus increasing disintegration time for the compact.
The desirability of providing lubrication only on the tablet sides or lands is indicated by prior efforts to obtain external lubrication of the die surfaces. Various methods and techniques of spraying or insufflating lubricants in solution or as small particle size solids have been used. These methods require elaborate mechanical components, do not precisely or uniformly deposit lubricant films where needed and are difficult to regulate and adjust for changes in tableting rates.
US. Pat. No. 3,l58,l l 1 discloses a timed spray to lubricate thepunch and die surfaces, the lubricant being dispersed in and distributed by an aerosol propellant.
U.S. Pat. No. 3,042,531 teaches a dual cycle compression system in which a tablet containing only lubricant and carrier is first compressed within a die and then ejected leaving a residue of lubricant on the punch and die surfaces providing external lubrication for a second active granulation which is subsequently introduced and compressed.
SUMMARY OF THE INVENTION The invention sought to be patented in a principal composition aspect resides in the concept of finely divided particles of solid hydrophobic tableting lubricant, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath.
The tangible embodiments of the principal composition aspect of the invention possess the applied use characteristic of supplying necessary lubrication at points of high shear when present in a tableting formulation subject to compression according to standard methods for compact formation. The hydrophilic envelope will selectively rupture at points of high shear such as the compact-die wall interface thus releasing the entrapped lubricant where it is needed. The enrobed solid hydrophobic lubricant particles in the interior of the compact as well as on the top and bottom surfaces will remain intact and present none of the antiadherent, hydrophobic characteristic properties of conventional, unprocessed lubricants.
The invention sought to be patented in a second composition aspect resides in the concept of a solid compact comprising finely divided particles of solid hydrophobic tableting lubricant, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath.
The tangible embodiments of the second composition aspect of the invention possess the applied use characteristic of being compacts with improved disintegration characteristics capable of formation by standard tableting procedures known in the art.
The invention sought to be patented in a principal process aspect resides in the concept of a process for the production of a compact which comprises incorporating in a mixture to be compacted finely divided particles of solid hydrophobic tableting lubricant, a substantial proportion of said particles being enrobed in a hydrophilic friable sheath, and applying thereto a sufficient compressive force.
DESCRIPTION OF THE PREFERRED EMBODIMENTS In accordance with the present invention a method is now provided whereby conventional tableting equipment and standard tableting procedures are utilized to prepare compacted tablets having improved disintegration characteristics.
The conventional tableting excipients such as binders, fillers, glidants, disintegrants, flavors and colorants may be mixed with a specially prepared enrobed solid hydrophobic lubricant before compaction. This solid hydrophobic lubricant has previously been treated to enclose it within a non-hydrophobic, friable sheath or envelope. This relatively inelastic envelope is designed to selectively rupture only at areas of high shear during compaction, such as the tablet-die wall interface, and remain intact in the interior of the tablet. Thus, the entrapped solid hydrophobic lubricant released from the ruptured enrobed lubricant particle functions only where actually required. The enrobed lubricant particles in the interior of the tablet remain intact and present none of the anti-adherent, hydrophobic properties of conventional, unprocessed lubricants. Thus, dispersal of fluids within the tablet interior is facilitated and the availability of the contained active ingredient is improved. The enrobed particles on the top and bottom of the tablet also remain substantially intact, thus providing free entry of the dissolution fluid. These surface particles, while subjected to high compressive forces during compaction are not ruptured, because no true shearing or sliding forces are exerted on these areas. Shear, in this context, is considered as stress resulting from applied forces that cause two contiguous surfaces to slide relatively to each other in a direction parallel to their plane of contact. The designed mechanical function of this method may be visually indicated by dye tracers incorporated in the envelope surrounding the lubricant particle. The sides or lands of the other wise uncolored compressed tablets show dye streaks parallel to the path of ejection, while examination of bisected tablets show intact unchanged enrobed particles in the tablet interior.
The enrobed solid hydrophobic lubricants of the present invention can be prepared by a variety of processes, such as:
Dispersion of solid hydrophobic tableting lubricant particles in molten mannitol, polyethylene glycol 4,000, 6,000 and 20,000, or other thermostable hydrophilic materials whereby milling or other methods of particle size reduction, after solidification, results in substantial entrapment of lubricant particles in a solid non-hydrophobic matrix;
Coating of the solid hydrophobic tableting lubricant particles with a hydrophilic material by spray drying or spray chilling technique;
Formation of hydrophilic micropellets from geletin, gum arabic, methyl cellulose, polyvinyl, alcohol, or the like, said micropellets containing solid hydrophobic tableting lubricant particles. The technique for preparation of micropellets containing particulate material is described in N. Tanaka, S. Takino, and I. Utsumi, J. Pharm. Sci., 52, 664 (1963).
Any of the various solid hydrophobic tableting lubricants may be used in this invention. Among these are magnesium stearate, calcium stearate, talcum, fatty acids, stearic acid, and powdered vegetable stearine. Other suitable tableting lubricants will readily suggest themselves and the utilization in the practice of the invention of any of a vast number of substances suitable as lubricants is well within the skill of the art.
Many hydrophilic substances may be utilized as the coating materials in the present invention. Among the hydrophilic mate ials contemplated by the present invention are such substances as gelatin, gum arabic, methyl cellulose, carboxymethylcellulose, polyvinyl alcohol, mannitol, polyethylene glycol 4,000, 6,000, and 20,000, and other hydrophilic materials which will be obvious to those skilled in the art. There is no criticality in the use of any particular lubricant or hydrophilic Substance. The thickness of the enrobing material which surrounds the lubricant particles is not critical. The shearing forces generated during compaction are extremely large and are more than sufficient to rupture the various sheath thicknesses which may be applied by the methods described in this invention and other methods known in the art. The optimal thickness of the friable sheath will vary with the particular substances utilized, or the particular coating procedures used; however, the optimal thickness, or optimal range of thicknesses for a particular combination of lubricant and sheathing material may be readily determined by those skilled in the art.
It will be apparent to those skilled in the art that the compacts prepared utilizing the present invention may be multilayer compacts and have various different shapes and sizes. Further, that these compacts once formed may be coded and/or coated by a variety of procedures well-known to those skilled in the art. Still further, they may be subjected to a polishing procedure or other routine processes which have been carried out on compacts prior to this invention.
While it is the main object of this invention to provide an improved method of preparation of pharmaceutical compacts which possess an improved dissolution rate, it will be obvious to those skilled in the art that this improved method may be applied to compacts other than those which contain a medicament. Thus, compacted coloring and flavoring materials, spices, detergents, and even placebo tablets may be prepared utilizing the improved method of this invention.
Additional advantages of this invention include the improvement of physical properties of compressed tablets even where availability of the actives is not a factor. As an example, harder, less friable and more rapidly disintegrating tablets may be obtained with the enrobed solid hydrophobic lubricant particles of the invention than with an equivalent quantity of unprocesses lubricant.
The following non-limiting examples illustrate the best mode contemplated by the inventor of carrying out the processes of the invention.
EXAMPLE I 10% Magnesium Stearate Enrobed in Polyethylene Glycol 4000, U. S. P.
Polyethylene glycol 4000 g.) is heated until molten (6065 C. and dry, finely powdered magnesium stearate U.S.P. (10 g.) is added with mechanical stirring. This stirred dispersion is cooled to room temperature (ca. 25 C.) and chilled further with solid carbon dioxide. The solid is milled through a US. No. 30 screen producing the enrobed tableting lubricant which is suitable for use in conventional tableting procedures.
EXAMPLE ll 33% Magnesium Stearate Enrobed in Gelatin To a suspension of gelatin (40 g.) in water (200 g.) is added finely powdered magnesium stearate USP. (20 g.) with rapid stirring. This mixture is warmed on a steam bath to form a solution and poured into mineral oil (600 g.) heated to ca. 5560 C. The total mixture is stirred at 1822 r.p.m. for 5 minutes and quickly cooled to ca. 5 C. producing gelatin micropellets containing magnesium stearate. The micropellets are washed with isopropanol and dried. The dried micropellets produced in this manner are suitable for use as a lubricant in conventional tableting procedures.
EXAMPLE lll Calcium Stearate Enrobed in Gelatin by Spray Drying Dry powdered calcium stearate g.) is suspended in a 1% gelatin solution (500 cc.) and the suspension is spray dried to remove the water. In this mar ner gelatin coated calcium stearate particles are obtained which are suitable for use as a tableting lubricant in a conventional tableting procedure.
EXAMPLE lV Talc Enrobed in Polyethylene Glycol 6000 by Spray Chilling Dry powdered talc (25 g.) is suspended in molten polyethylene glycol 6,000 (250 g.) and stirred until homogeneous. This suspension is sprayed into a chilled chamber with cold air causing the polyethylene glycol 6,000 to solidify about the tale particles. In this manner talc particles coated with polyethylene glycol 6,000 may be obtained which are suitable for use as a tableting lubricant in a conventional tableting procedure.
EXAMPLE V Tablets having the following composition are prepared with conventional tableting equipment:
Tablet disintegration time was reduced from 23' minutes for a control tablet containing a conventional lubricant to 17 minutes for a tablet containing an equivalent amount of the enrobed lubricant.
EXAMPLE Vl Antibiotic tablets having the following composition and showing the superior dissolution characteristics tabulated are prepared as follows:
Ingredient mg. per tablet Potassium Penicillin G, U.S.P. 166.0 Gelatin Enrobed Lubricant [8.0 (33% Magnesium stearate. U.S.P.) Calcium Carbonate, U.S.P. 222.0 Silicon Dioxide 22.0 Mcthylcellulose, U.S.P., 400 cps. 40.0 468.0
Total Weight The penicillin availability is indicated by continu ously recorded fluorometric assay. T and T is time in minutes necessary for dissolution of 50% and 80%,
respectively. of the total potassium penicillin per tablet.
71 in soln in 60 mins.
72 in sol'n T T,. in 30 mins.
Control 25 56 57 82 Tablet (containing unprocessed lubricant) Tablet (made with equivalent amount of enrobed lubricant) bricant being enrobed in a hydrophilic friable sheath,
said sheathing material being selected from the group consisting of mannitol, polyethylene glycol 4,000, 6,000, and 20,000, gelatin, methyl cellulose, carboxymethylcellulose, gum arabic, and polyvinyl alcohol; said enrobed tableting lubricant imparting a reduction in dissolution time to a compacted pharmaceutical dosage form when incorporated in said compacted pharmaceutical dosage form, as compared to said lubricant when not enrobed.
2. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is magnesium stearate and the hydrophilic friable sheathing material is poly ethylene glycol 4000. V
3.'The composition of claim 1 wherein the solid hydrophobic tableting lubricant is magnesium stearate and the hydrophilic friable sheathing material is gelatin.
4. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is calcium stearate and the hydrophilic friable sheathing material is gelatin.
5. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is talc and the hydrophilic friable sheathing material is polyethylene glycol 6,000.
6. A compressed pharmaceutical medicament tablet containing as tableting lubricant a tableting lubricant composition consisting essentially of micropellets of finely divided particles of solid hydrophobic tableting lubricant selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, talcum, and powdered vegetable stearine, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath, said sheathing material being selected from the group consisting of mannitol, polyethylene glycol 4,000, 6,000, and 20,000, gelatin, methyl cellulose, carboxymethylcellulose, gum arabic, and polyvinyl alcohol; said tablet having imparted, by said enrobed lubricant, reduced disintegration time compared to said lubricant if not enrobed.
Claims (6)
1. A TABLETING LUBRICANT COMPOSITION CONSISTING ESSENTIALLY OF MICROPELLETS OF FINELY DIVIDED PARTICLES OF SOLID HYDROPHOBIC TABLETING LUBRICANT SELECTED FROM THE GROUP CONSISTING OF MAGNESIUM STREARATE CALCIUM STEARATE STERARIC ACID TALCUM AND POWDERED VEGETABLE STEARINE A SUBSTANTIAL PROPORTON OF THE PARTICLES OF SAID LUBRICANT BEING ENROBED IN A HYDROPHILIC FRIABLE SHEATH SAID SHEATHING MATERIAL BEING SELECTED FROM THE GROUP CONSISTING OF MANNITOL POLYETHYLENE GLYCOL 4,000 6,000 AND 20,000 GELATIN METHYL CELLULOSE CARBOXYMETHYLCELLULOSE GUM, ARABIC AND POLYVINYL ALCOHOL SAID ENROBED TABLETING LUBRICANT IMPARTING A REDUCTION IN DISSOLUTION TIME TO A COMPACTED PHARMACEUTICAL DOSAGE FORM WHEN INCORPORATED IN SAID COMPACTED PHARMACEUTICAL DOSAGE FORM AS COMPARED TO SAID LUBRICANT WHEN NOT ENROBED.
2. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is magnesium stearate and the hydrophilic friable sheathing material is polyethylene glycol 4000.
3. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is magnesium stearate and the hydrophilic friable sheathing material is gelatin.
4. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is calcium stearate and the hydrophilic friable sheathing material is gelatin.
5. The composition of claim 1 wherein the solid hydrophobic tableting lubricant is talc and the hydrophilic friable sheathing material is polyethylene glycol 6,000.
6. A compressed pharmaceutical medicament tablet containing as tableting lubricant a tableting lubricant composition consisting essentially of micropellets of finely divided particles of solid hydrophobic tableting lubricant selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, talcum, and powdered vegetable stearine, a substantial proportion of the particles of said lubricant being enrobed in a hydrophilic friable sheath, said sheathing material being selected from the group consisting of mannitol, polyethylene glycol 4,000, 6,000, and 20,000, gelatin, methyl cellulose, carboxymethylcellulose, gum arabic, and polyvinyl alcohol; said tablet having imparted, by said enrobed lubricant, redUced disintegration time compared to said lubricant if not enrobed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US449171A US3908003A (en) | 1971-07-02 | 1974-03-07 | Enrobed solid hydrophobic tableting lubricants and compositions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15956971A | 1971-07-02 | 1971-07-02 | |
| US449171A US3908003A (en) | 1971-07-02 | 1974-03-07 | Enrobed solid hydrophobic tableting lubricants and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3908003A true US3908003A (en) | 1975-09-23 |
Family
ID=26856088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US449171A Expired - Lifetime US3908003A (en) | 1971-07-02 | 1974-03-07 | Enrobed solid hydrophobic tableting lubricants and compositions |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3908003A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127645A (en) * | 1976-05-21 | 1978-11-28 | Life Savers, Inc. | Effervescent tablet and method |
| US4254099A (en) * | 1978-10-18 | 1981-03-03 | Beiersdorf Aktiengesellschaft | Pharmaceutical tablet composition |
| US4465660A (en) * | 1981-04-01 | 1984-08-14 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| US4499066A (en) * | 1981-08-05 | 1985-02-12 | Farmitalia Carlo Erba S.P.A. | Pharmaceutical sustained-release compositions |
| US4547358A (en) * | 1980-05-06 | 1985-10-15 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| US5436011A (en) * | 1993-04-16 | 1995-07-25 | Bristol-Myers Squibb Company | Solid pharmaceutical dosage form and a method for reducing abrasion |
| US20100021540A1 (en) * | 2008-02-28 | 2010-01-28 | Abbott Laboratories | Tablets and Preparation Thereof |
| JP2010513329A (en) * | 2006-12-20 | 2010-04-30 | ミラン ファーマシューティカルズ ユーエルシー | Pharmaceutical composition comprising hot melt granulated lubricant |
| US20100297268A1 (en) * | 2008-01-23 | 2010-11-25 | Fujifilm Corporation | Agent for increasing blood adiponectin quantity |
| AU2014201170B2 (en) * | 2006-12-20 | 2015-09-24 | Mylan Pharmaceuticals Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3210208A (en) * | 1962-05-01 | 1965-10-05 | Smith Kline French Lab | Process of coating organopolysiloxane particles |
| US3382150A (en) * | 1962-05-01 | 1968-05-07 | Smith Kline French Lab | Spray-dried coated organopolysiloxane oral pharmaceutical or veterinary composition |
| US3518345A (en) * | 1967-10-05 | 1970-06-30 | Miles Lab | Tableting lubricant |
| US3518343A (en) * | 1967-10-02 | 1970-06-30 | Miles Lab | Effervescent tablet and process for making same |
| US3518344A (en) * | 1967-10-02 | 1970-06-30 | Miles Lab | Tableting lubricant |
| US3619462A (en) * | 1969-12-29 | 1971-11-09 | Miles Lab | Tableting lubricant |
-
1974
- 1974-03-07 US US449171A patent/US3908003A/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3210208A (en) * | 1962-05-01 | 1965-10-05 | Smith Kline French Lab | Process of coating organopolysiloxane particles |
| US3382150A (en) * | 1962-05-01 | 1968-05-07 | Smith Kline French Lab | Spray-dried coated organopolysiloxane oral pharmaceutical or veterinary composition |
| US3518343A (en) * | 1967-10-02 | 1970-06-30 | Miles Lab | Effervescent tablet and process for making same |
| US3518344A (en) * | 1967-10-02 | 1970-06-30 | Miles Lab | Tableting lubricant |
| US3518345A (en) * | 1967-10-05 | 1970-06-30 | Miles Lab | Tableting lubricant |
| US3619462A (en) * | 1969-12-29 | 1971-11-09 | Miles Lab | Tableting lubricant |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4127645A (en) * | 1976-05-21 | 1978-11-28 | Life Savers, Inc. | Effervescent tablet and method |
| US4254099A (en) * | 1978-10-18 | 1981-03-03 | Beiersdorf Aktiengesellschaft | Pharmaceutical tablet composition |
| US4547358A (en) * | 1980-05-06 | 1985-10-15 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| US4465660A (en) * | 1981-04-01 | 1984-08-14 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| US4499066A (en) * | 1981-08-05 | 1985-02-12 | Farmitalia Carlo Erba S.P.A. | Pharmaceutical sustained-release compositions |
| US5436011A (en) * | 1993-04-16 | 1995-07-25 | Bristol-Myers Squibb Company | Solid pharmaceutical dosage form and a method for reducing abrasion |
| JP2010513329A (en) * | 2006-12-20 | 2010-04-30 | ミラン ファーマシューティカルズ ユーエルシー | Pharmaceutical composition comprising hot melt granulated lubricant |
| US20100120723A1 (en) * | 2006-12-20 | 2010-05-13 | Mostafa Akbarieh | Pharmaceutical composition comprising a hot-melt granulated lubricant |
| AU2014201170B2 (en) * | 2006-12-20 | 2015-09-24 | Mylan Pharmaceuticals Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
| US20100297268A1 (en) * | 2008-01-23 | 2010-11-25 | Fujifilm Corporation | Agent for increasing blood adiponectin quantity |
| US20100021540A1 (en) * | 2008-02-28 | 2010-01-28 | Abbott Laboratories | Tablets and Preparation Thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3670065A (en) | Process for producing dosage units of a type resembling tablets | |
| US4483847A (en) | Process for the manufacture of a pharmaceutical composition with a retarded liberation of active material | |
| US3279998A (en) | Method of preparing sustained release tablets | |
| DE68926432T2 (en) | Solid encapsulated drug, method and device for its manufacture | |
| US3147187A (en) | Sustained release pharmaceutical | |
| DE69817010T2 (en) | SPHEROIDS, PROCESS FOR PRODUCING THE SAME AND MEDICINAL PRODUCTS CONTAINING THEM | |
| DE69123075T2 (en) | Coated composition and process for its manufacture | |
| US3908003A (en) | Enrobed solid hydrophobic tableting lubricants and compositions | |
| US5453283A (en) | Orally administered solvent-free pharmaceutical preparation with delayed active-substance release, and a method of preparing the preparation | |
| US6194005B1 (en) | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix | |
| DE3030622A1 (en) | DIVISIBLE TABLET WITH CONTROLLED AND DELAYED DELIVERY OF ACTIVE SUBSTANCES | |
| US3632778A (en) | Tablets containing l-dopa | |
| US2841528A (en) | Method of making fused tablets | |
| US2757124A (en) | Tablets and method of producing same | |
| US4151274A (en) | Process and composition for the production of suppositories | |
| US20090041829A1 (en) | Pharmaceutical dosage forms comprising a lipid phase | |
| US3247064A (en) | Multivitamin tablet stabilized with porous silica | |
| EP0239983B1 (en) | Bricks made of pellets | |
| US3857933A (en) | Process for the manufacture of a drug dosage form permitting controlled release of active ingredient | |
| DE60027601T2 (en) | DRUG PREPARATION WITH CONTROLLED RELEASE CONTAINING TRAMADOL HYDROCHLORIDE | |
| EP0948321B1 (en) | Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance | |
| DE60002089T2 (en) | LOW-DOSED TABLETS AND METHOD FOR THE PRODUCTION THEREOF | |
| US3655852A (en) | Method of forming a stable vitamin e-c granulation | |
| DE2146174A1 (en) | Direct compression tablets and process for their manufacture | |
| DE1617418C3 (en) | Manufacture of solid drug forms with delayed release of active ingredients |